Gainers
- SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q3 earnings came out 3 days ago.
- Aytu BioPharma (NASDAQ:AYTU) shares rose 45.87% to $2.65. The market value of their outstanding shares is at $19.7 million. The company's, Q1 earnings came out yesterday.
- Cingulate (NASDAQ:CING) stock moved upwards by 29.73% to $4.87. The company's market cap stands at $56.1 million. As per the press release, Q3 earnings came out 2 days ago.
- Gain Therapeutics (NASDAQ:GANX) shares rose 27.62% to $1.2. The company's market cap stands at $41.0 million.
- CEL-SCI (AMEX:CVM) shares rose 24.09% to $2.06. The market value of their outstanding shares is at $29.1 million.
- Greenwich LifeSciences (NASDAQ:GLSI) stock rose 23.21% to $16.95. The market value of their outstanding shares is at $201.9 million. As per the press release, Q3 earnings came out yesterday.
Losers
- Cue Biopharma (NASDAQ:CUE) stock fell 51.2% to $6.88 during Tuesday's regular session. The company's market cap stands at $102.4 million. As per the news, the Q3 earnings report came out yesterday.
- Scilex Holding (NASDAQ:SCLX) shares fell 48.4% to $0.65. The market value of their outstanding shares is at $8.7 million.
- Kyntra Bio (NASDAQ:KYNB) stock declined by 31.25% to $2.2. The company's market cap stands at $12.9 million. As per the news, the Q3 earnings report came out yesterday.
- Dare Bioscience (NASDAQ:DARE) shares decreased by 24.84% to $0.44. The company's market cap stands at $11.4 million. The company's, Q3 earnings came out yesterday.
- Akanda (NASDAQ:AKAN) shares fell 23.76% to $1.69. The market value of their outstanding shares is at $5.8 million.
- Co-Diagnostics (NASDAQ:CODX) shares fell 19.92% to $0.18. The market value of their outstanding shares is at $2.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


